(StatePoint) This article is sponsored by Otsuka America Pharmaceutical, Inc. Each year, September 4 marks Polycystic Kidney Disease (PKD) Awareness Day, an initiative that aims to increase public ...

Clinicians managing patients with ADPKD should have high clinical suspicion for post-transplant diabetes, infection, and thromboembolism. Patients with autosomal dominant polycystic kidney disease ...

Clinicians should monitor patients with stones, even if they are asymptomatic, to slow kidney function decline, investigators suggest. Even asymptomatic kidney stones may spur kidney function decline ...

Washington, DC-Rapamycin, aka sirolimus, a drug already used as an immunosuppressant agent in kidney transplantation, may prove to be an effective treatment for autosomal dominant polycystic kidney ...

—A new investigation reviewed existing evidence to clarify which factors are most likely to elevate the risk of developing intracranial aneurysms in asymptomatic patients with autosomal dominant ...

SEOUL, South Korea, June 12, 2025 /PRNewswire/ -- Mezzion Pharma Co., Ltd. (Mezzion), a leader in rare disease therapeutics, today announced the expansion of its udenafil pipeline with the initiation ...

$54.5 million in seed financing led by founding investor 5AM Ventures alongside Atlas Venture, OrbiMed and Qiming Venture Partners USA Renasant Bio (Renasant), announced its launch today to advance ...

Novartis AG (NYSE:NVS) agreed to acquire Regulus Therapeutics Inc. (NASDAQ:RGLS) on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion. The upfront cash portion of the ...

A new study examined the records of 4452 Asian patients with ADPKD treated at 2 tertiary-care centers over a period of 15 years. Patients with ADPKD had higher rates of post-transplant diabetes ...